

KEYSTONE SYMPOSIA

on Molecular and Cellular Biology

21st Century Drug Discovery and Development for Global Health (S3)

October 17-20, 2018 • Hotel Palace Berlin • Berlin, Germany

Scientific Organizers: Ken Duncan, Elizabeth Winzeler and Lluís Ballell

Part of the Keystone Symposia Global Health Series, supported by the Bill & Melinda Gates Foundation

Abstract & Scholarship Deadline: June 19, 2018 / Abstract Deadline: July 17, 2018 / Discounted Registration Deadline: August 16, 2018

WEDNESDAY, OCTOBER 17

Arrival and Registration

THURSDAY, OCTOBER 18

New Therapeutics for Global Health

Nathalie Strub Wourgaft, Drugs for Neglected Diseases initiative, DNDi, Switzerland

Transformative New Therapies for Human African trypanosomiasis

Thierry T. Diagana, Novartis Institute for Tropical Diseases, Singapore
Progress with Cipargamin and KAF156 in Phase 2 Development for Treatment of Malaria

Lluís Ballell, GlaxoSmithKline, Spain
Novel Drug Candidates to Address the Threat of Antibacterial Resistance in the Developing World; TB and Shigella

Short Talk(s) Chosen from Abstracts

Robust Target Validation – What Does it Mean?

Elizabeth A. Winzeler, University of California, San Diego, USA
Multi-Disciplinary Approach to Target Identification, Validation and Prioritization in Plasmodium

Dirk Schnappinger, Weill Cornell Medical College, USA
Combining Chemical Probes and Genetic Knockdowns to Validate Drug Targets in Mycobacterium tuberculosis

Boris Striepen, University of Pennsylvania, USA
Using Molecular Genetics to Understand and Combat Cryptosporidium.

Short Talk Chosen from Abstracts

FRIDAY, OCTOBER 19

Importance of Chemical Diversity in Seeking New Leads

Ghotas Evindar, GlaxoSmithKline, USA
Experience with DNA-Encoded Libraries in Search for New Leads against TB and Malaria

E. Paige Stout, Sirenas, USA
Application of Data-Mining and Deep Learning to Identify New Leads from Marine Natural Products

Judy A. Sakanari, University of California, San Francisco, USA
Screening a Repurposing Library for Agents with Macrofilaricidal Activity

Charles E. Mowbray, Drugs for Neglected Diseases Initiative, Switzerland
A New Era of Orally Active Treatments for Leishmaniasis Patients

Short Talk(s) Chosen from Abstracts

Workshop 1: Novel Clinical Trial Design

Short Talks Chosen from Abstracts

Alternative Approaches to Drug Delivery – Opportunities and Challenges

Speaker to be Announced

Andrew Martin Bellinger, Lyndra, USA

Development of Oral, Ultra Long-Lasting, Sustained Release Therapies in the Fight against Malaria and HIV

Arnab Chatterjee, Calibr, USA

Chemoprophylaxis for Prevention of Malaria Infection

Short Talk Chosen from Abstracts

Poster Session 1

SATURDAY, OCTOBER 20

Improving Target and Phenotypic-based Approaches

Leann M. Tilley, University of Melbourne, Australia
The Proteasome as a Target for New Antimalarial Drugs

Kirsten Hanson, University of Texas, San Antonio, USA
Profiling Compounds against Liver Stage Malaria

Deborah Hung, Broad Institute, USA
Multiplex Screening of an M. tuberculosis Hypomorph Library Simultaneously Identifies Lead and Target

Marc Gitzinger, BioVersys AG, Switzerland
A SMART Approach to Reversing Drug Resistance in TB

Short Talk(s) Chosen from Abstracts

Poster Session 2

Workshop 2: Opportunities for Repurposing to Discover New Candidates or Mature Starting Points

Short Talks Chosen from Abstracts

Translational Tools for Predicting Efficacy and Resistance

Wesley C. Van Voorhis, University of Washington, USA
Pharmacodynamic Modeling of Anti-Cryptosporidium Drug Efficacy

Speaker to be Announced

Speaker to be Announced

Short Talk Chosen from Abstracts

SUNDAY, OCTOBER 21

Departure